On March 11, New Mexico Governor Michelle Lujan Grisham (D) signed the budget for the upcoming fiscal year into law, and in doing so, underlined the state’s position at the vanguard of alternative mental health treatments.
Embedded within the finalized appropriation is a late addition: a pioneering directive to allocate $630,000 to the state’s Psilocybin Treatment Equity Fund, newly established under New Mexico’s Medical Psilocybin Act.
Confirmation of the funding represents a big step forward in the state’s efforts to integrate psychedelic-assisted therapies into its broader behavioral health infrastructure. And the formal allocation of state funds to pay for psychedelic treatments for patients on low incomes is seen as a world first.
“To ensure all New Mexicans who qualify for the program would have access to it, not just those with financial resources.”
State Senator Jeff Steinborn (D) was one of the legislative champions of the 2025 legalization of psilocybin for medical purposes. He emphasized that the state’s financial support is what will ultimately dictate the efficacy and fairness of the entire enterprise.
“I’m excited that New Mexico has taken the next step in support of our Medical Psilocybin Treatment Program,” Sen. Steinborn told Filter following the budget’s approval. “An important part of our state law was the creation of an equity fund, to ensure all New Mexicans who qualify for the program would have access to it, not just those with financial resources. Through this funding provided by the legislature and governor, as well as additional investment in research into end-of-life anxiety, we are working to launch the best evidence-based program possible.”
In addition to the equity fund allocation, the budget authorizes a supplementary $300,000 earmarked for clinical research at the University of New Mexico into treating end-of-life anxiety with psilocybin—the hallucinogenic compound found in certain mushrooms.
New Mexico will be a critical testing ground for medical access to psychedelics as it navigates the challenges of implementation. Its schedule is ambitious. In December 2025, state health officials announced concrete plans to launch the program by the end of 2026. This means rolling out the regulatory and clinical framework a full year ahead of the initially imposed legislative deadline.
When the program opens its doors to patients, New Mexico will become the third state to launch a state-regulated psilocybin program after Oregon and Colorado. However, while Oregon and Colorado have adopted models that allow for supported adult use and broader therapeutic access outside of strict medical confines, New Mexico’s program will be fundamentally clinical and medicalized. It’s designed to provide highly supervised treatment for specific, severe qualifying medical conditions—including major treatment-resistant depression, severe post-traumatic stress disorder (PTSD), chronic substance use disorders, and specialized end-of-life care.
The journey to secure the $630,000 for the fund was neither guaranteed nor simple. A coalition worked to pressure lawmakers.
But in the United States, a medicalized model immediately raises questions around whether people will be able to access it on the basis of need, rather than ability to pay. That’s what the Psilocybin Treatment Equity Fund is intended to address.
The journey to secure the $630,000 for the fund was neither guaranteed nor simple. When the 2026 legislative session convened in Santa Fe in January, the process began without any proposed money for the fund in either the executive or legislative budget recommendations. The omission threatened to leave the equity provisions of the Medical Psilocybin Act as an unfunded mandate, potentially delaying access for the state’s most vulnerable populations.
In response, a coalition of statewide psychedelic community members, health care providers and other advocates worked to pressure lawmakers. The coalition drafted and circulated a formal petition and letter to state legislators, urging them to ensure the funding was provided. Their efforts paid off.
Denali Wilson, director of strategy support for the Healing Advocacy Fund in New Mexico, characterized the budget allocation as a monumental victory for patient advocacy and an indicator of the state’s commitment to equitable health care.
The legislature’s decision “sends a clear message: This new model is intended to be accessible to the communities it is designed to serve.”
“Full funding of the Treatment Equity Fund marks the beginning of a bold new chapter in state-led health innovation,” Wilson told Filter. “As the nation’s first medically integrated psilocybin program, New Mexico is setting a model the rest of the country will be watching closely—particularly when it comes to affordability, access and equity.”
The legislature’s decision, she continued, “sends a clear message: This new model is intended to be accessible to the communities it is designed to serve. Ensuring that ability to pay is not a barrier to accessing life-saving services is essential to the program’s success.”
Wilson added that the late addition to the budget underscores the power of civic engagement in shaping emergent health policies.“Community members and advocates rallied to highlight the need, and our lawmakers and Governor responded,” she said. “We are grateful to the governor and the legislature for their leadership, and especially thank Senators Jeff Steinborn, Jay Block, Nicole Tobiassen, and Martin Hickey, and Representative Stefani Lord for their support of equity and research.”
The infusion of state dollars into the psychedelic therapy framework is largely made possible by New Mexico’s unique economic positioning. It manages significant, continuous oil and gas revenues through a series of state-run trust funds. State lawmakers have the discretionary authority to allocate portions of these funds to invest in education, infrastructure, state services and public health initiatives. In this unprecedented instance, legislators have directed a fraction of that fossil fuel revenue toward establishing sustainable psilocybin-assisted therapy services.
“Psilocybin will be an important new tool to relieve anxiety and depression in patients facing end of life.”
The program’s focus on end-of-life care has also drawn national attention. Attorney Kathryn Tucker, advocacy director for the National Psychedelics Association, serves as co-counsel behind an ongoing legal petition to formally reschedule psilocybin under the federal Controlled Substances Act—currently under review by the US Department of Health and Human Services. Tucker applauded New Mexico’s move to provide compassionate care.
“Great to see the funding come through for the New Mexico Medical Psilocybin Act,” she told Filter, adding that in her opinion, the legislation “is a great model for other states.”
Tucker, who also serves as a special advocacy advisor for the National Psychedelics Association, highlighted the intersection between psilocybin therapy and existing palliative care laws. “New Mexico is among the states that allows Medical Aid in Dying,” she noted, “empowering terminally ill people to obtain medications prescribed by their physician to advance the time of death. Regardless what one thinks of MAID, all agree no one ought to choose it due to unrelieved suffering. Psilocybin will be an important new tool to relieve anxiety and depression in patients facing end of life.”
Beyond the immediate public health implications, policy experts argue that funding psilocybin therapy is a sound economic strategy for state governments burdened by the spiraling costs of conventional mental health treatments. Conventional approaches to treatment-resistant depression and severe PTSD may involve decades of prescription medications, intensive outpatient programs and hospitalizations—costs often absorbed by state-funded Medicaid programs.
“New Mexico just made a smart bet, and it starts with getting the math right. The framing that psilocybin therapy is too expensive has failed to compare it to anything.”
Sam Chapman, founder and executive director of the Center for Psychedelic Policy, suggested that New Mexico’s initial financial investment will yield massive downstream savings.
“New Mexico just made a smart bet, and it starts with getting the math right,” he told Filter. “The framing that psilocybin therapy is too expensive has failed to compare it to anything. Compare it to the tens of billions of dollars states are spending on medication cycles, repeated hospitalizations, and chronic treatment that produces modest outcomes, and the calculus inverts completely.”
“Psilocybin therapy isn’t a luxury alternative,” Chapman continued. “It’s about becoming the most cost-effective intervention in the behavioral health toolbox. New Mexico sees that, and the states that do the math early are the ones that stand to lead the country on behavioral health for the next decade to come.”
Despite the optimism surrounding the budget signing and the macroeconomic arguments for psychedelic medicine, local organizers caution that the state appropriation is only the first piece of a much larger financial puzzle. The practical, day-to-day operations of a medical psilocybin clinic involve significant overheads—including the high costs of licensing, securing specialized clinical spaces and compensating highly trained facilitators, who must sit with patients for treatment sessions that can last upwards of six hours.
“The overall impact will depend on the cost of facilitating treatment for participants, which remains largely unknown at this time.”
Deborah Thorne, founder of Sol Tryp—a Las Cruces-based nonprofit organization dedicated to “promoting psychedelic healing, methods, teachings, research, and reciprocity”—said that while the budget allocation is crucial, the real-world costs of treatment for vulnerable populations are still difficult to quantify.
“The $630,000 Treatment Equity Fund will provide an important initial contribution to the program,” Thorne told Filter, noting the complexity of the upcoming rollout. However, she warned that “the overall impact will depend on the cost of facilitating treatment for participants, which remains largely unknown at this time.”
Because state funds alone may not be sufficient to subsidize the full scope of patient needs once the program opens in December 2026, Thorne stressed the ongoing need for private and philanthropic support. “It is essential that nonprofits and community advocacy organizations continue to engage in fundraising and resource development efforts to help ensure the program’s long-term sustainability,” she said.
As New Mexico Department of Health regulators spend at least the next nine months finalizing the specific rules, licensing requirements, and safety protocols for the psilocybin program, many medical, legal, and public policy eyes will be fixed on Santa Fe. The nature of the Psilocybin Treatment Equity Fund rollout could determine whether psychedelic therapy remains an exclusive option for the wealthy, or become a standard, accessible cornerstone of public health.
Photograph by Alan Rockefeller via Wikimedia Commons/Creative Commons 3.0
